Last reviewed · How we verify
NCT00508911
A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills
Phase 1 trial testing GW876008 in Social Phobia in 4 participants. Terminated before completion.
22 October 2007
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 4 |
| Start date | 8 June 2007 |
| Primary completion | 22 October 2007 |
| Estimated completion | 22 October 2007 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
Conditions studied
- Social Phobia — all drugs for Social Phobia →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 18 to 45, female only, with Social Phobia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be conducted in healthy female volunteers to investigate the effect of GW876008 on the pharmacokinetics of oral contraceptive pills.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Progress in corticotropin-releasing factor-1 antagonist development.
Zorrilla EP, Koob GF. · · 2010 · cited 131× · PMID 20206287 · DOI 10.1016/j.drudis.2010.02.011
Verify or expand the search:
- PubMed search for NCT00508911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GW876008
Trials testing the same drug.
- NCT00385099 — Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome · Phase 2 · completed
- NCT00397722 — Treatment Of Patients With Social Anxiety Disorder · Phase 2 · completed
- NCT00421707 — Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome · Phase 2 · completed
Other recruiting trials for Social Phobia
Currently open trials in the same condition.
- NCT06564402 — Augmentation of Exposure Using Positive Mental Rehearsal in Individuals With Increased Social Anxiety · NA · recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00508911 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 4 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00508911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing